Skip to main content
SLXN
NASDAQ Life Sciences

Silexion Therapeutics 报告 600 万美元现金，胰腺癌药物进入 2/3 期试验

feedReported by GlobeNewswire
Sentiment info
Neutral
Importance info
8
Price
$1.56
Mkt Cap
$5.196M
52W Low
$1.42
52W High
$22.36
Market data snapshot near publication time

summarizeSummary

Silexion Therapeutics 报告了其 2025 年第四季度和全年财务结果，年末约有 600 万美元的现金和现金等价物。虽然公司强调了加强其财务状况和重新获得纳斯达克合规的地位，但这种现金余额为临床阶段生物技术公司提供了有限的跑道，尤其考虑到其市值。同时，Silexion 提供了重大商业更新，详细介绍了 SIL204 在多个 KRAS 突变和癌症类型中的积极的临床前发现、完成的毒理学研究以及在以色列提交的针对局部进展的胰腺癌的 2/3 期临床试验申请。公司预计将在 2026 年第二季度启动 2/3 期试验。这种更新呈现出一个混合的图景，具有前景的临床进展与紧张的财务状况相平衡，后者可能需要进一步的资本增加。

在该公告发布时，SLXN的交易价格为$1.56，交易所为NASDAQ，所属行业为Life Sciences，市值约为$519.6万。 52周交易区间为$1.42至$22.36。 这则新闻被评估为中性市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed SLXN - Latest Insights

SLXN
Apr 28, 2026, 4:05 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Silexion Adjourns Shareholder Meeting to Vote on Massive Dilution, Reverse Split, and Equity Plan
Sentiment: Negative
View Wiseek Article
SLXN
Apr 28, 2026, 8:58 AM EDT
Filing Type: 8-K
Importance Score:
8
Silexion Therapeutics Submits Phase 2/3 CTA for Pancreatic Cancer Drug in Germany
Sentiment: Positive
View Wiseek Article
SLXN
Apr 28, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
8
Silexion Submits Pivotal Phase 2/3 CTA for Pancreatic Cancer Drug to Germany, Expanding EU Trial
Sentiment: Positive
View Wiseek Article
SLXN
Apr 09, 2026, 4:26 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Shareholders to Vote on Massive Share Increase, Reverse Split, and Expanded Equity Plan Amidst Going Concern
Sentiment: Negative
View Wiseek Article
SLXN
Mar 31, 2026, 11:17 AM EDT
Filing Type: PRE 14A
Importance Score:
9
Silexion Re-Proposes Massive Share Increase, Reverse Split After Prior Rejection Amidst Delisting Risk
Sentiment: Negative
View Wiseek Article
SLXN
Mar 25, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Silexion Therapeutics Board Removes Director Ilan Levin Amidst Financial Distress
Sentiment: Negative
View Wiseek Article
SLXN
Mar 24, 2026, 9:08 AM EDT
Filing Type: 8-K
Importance Score:
9
Silexion Therapeutics Receives Approval for Phase 2/3 Pancreatic Cancer Trial
Sentiment: Positive
View Wiseek Article
SLXN
Mar 24, 2026, 8:37 AM EDT
Source: GlobeNewswire
Importance Score:
8
Silexion Therapeutics Gains Israeli Approval for Pivotal Phase 2/3 Pancreatic Cancer Trial
Sentiment: Positive
View Wiseek Article
SLXN
Mar 23, 2026, 4:32 PM EDT
Filing Type: 8-K
Importance Score:
9
Shareholders Reject Critical Capital Raise and Equity Plan Proposals Amidst Going Concern Warning
Sentiment: Negative
View Wiseek Article
SLXN
Mar 17, 2026, 5:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Silexion Therapeutics Reports $6M Cash, Advances Pancreatic Cancer Drug to Phase 2/3 Trial
Sentiment: Neutral
View Wiseek Article